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1. General methods for synthesis
General method for the synthesis of cyano substituted N-2-benzimidazolyl 
methoxybenzamides (21-22)
To a solution of corresponding benzoyl chlorides 2-3 in dry toluene, a solution of 2-amino-5(6)-
cyanobenzimidazole 18 in dry toluene was added dropwise, followed by the addition of Et3N. 
The reaction mixture was refluxed for several hours. After cooling the solution was 
concentrated and the obtained solid was filtered off and recrystallized from appropriate solvent. 
N-(5(6)-Cyanobenzimidazol-2-yl)-2,4-dimethoxybenzamide (21): This compound was prepared 
using above described method from 2,4-dimethoxybenzoyl chloride 2 (0.19 g, 0.95 mmol) and 
2-amino-5(6)-cyanobenzimidazole 18 (0.15 g, 0.95 mmol) in dry toluene (10 mL) followed by 
the addition of Et3N (0.19 mL, 1.33 mmol) after refluxing for 36 hours and recrystalization 
from methanol/acetone to obtain 0.11 g (36%) of light yellow powder; mp 236˗˗239 °C; 1H 
NMR (300 MHz, DMSO-d6) (δ/ppm): 12.71 (brs, 1H, NHbenzimidazole), 11.07 (s, 1H, NHamide), 
7.90 (d, J = 8.49 Hz, 1H, Harom), 7.89 (s, 1H, Harom), 7.62 (d, J = 8.25 Hz, 1H, Harom), 7.51 (dd, 
J1 = 8.27 Hz, J2 = 1.54 Hz, 1H, Harom), 6.77 (d, J = 2.01 Hz, 1H, Harom), 6.74 (dd, J1 = 8.64 Hz, 
J2 = 2.25 Hz, 1H, Harom), 4.01 (s, 3H, OCH3), 3.88 (s, 3H, OCH3); 13C NMR (150 MHz, DMSO-
d6) (δ/ppm): 164.8, 164.4, 159.7, 133.0, 113.6, 107.0, 99.2 (2C), 57.0, 56.2; Anal. Calcd. for 
C19H20N5O3: C, 63.52; H, 4.20; N, 17.22. Found: C, 63.35; H, 4.38; N, 17.38. 
N-(5(6)-Cyanobenzimidazol-2-yl)-3,4,5-trimethoxybenzamide (22): This compound was 
prepared using above described method from 3,4,5-trimethoxybenzoyl chloride 3 (0.50 g, 2.18 
mmol) and 2-amino-5(6)-cyanobenzimidazole 18 (0.35 g, 2.18 mmol) in dry toluene (40 mL) 
followed by the addition of Et3N (0.19 mL, 1.33 mmol) after refluxing for 24 hours and 
recrystalization from methanol to obtain 0.55 g (72%) of white powder; mp 247˗˗250 °C; 1H 
NMR (300 MHz, DMSO-d6) (δ/ppm): 12.75 (brs, 1H, NHbenzimidazole), 12.26 (s, 1H, NHamide), 
7.94 (d, J = 0.80 Hz, 1H,Harom), 7.65 (d, J = 8.28 Hz, 1H, Harom), 7.54 (dd, J1 = 8.27 Hz, J2 = 
1.55 Hz, 1H, Harom), 7.51 (s, 2H, Harom), 3.90 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.77 (s, 3H, 
OCH3); 13C NMR (150 MHz, DMSO-d6) (δ/ppm): 166.2, 153.2 (2C), 150.3, 141.7, 133.7, 
127.8, 125.6, 120.7 (2C), 107.1, 106.3 (3C), 103.4, 60.6, 56.9 (2C); Anal. Calcd. for 
C18H16N4O4: C, 61.54; H, 4.76; N, 15.68. Found: C, 61.36; H, 4.58; N, 15.90.
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General method for the synthesis of amidino substituted N-2-benzimidazolyl 
methoxybenzamides (38, 39, 43 and 44)
A stirred suspension of 5(6)-cyanobenzimidazol-2-yl substituted methoxybenzamides 21-22 in 
absolute ethanol was cooled in an ice-salt bath and was saturated with dry HCl gas. The reaction 
mixture was maintained at room temperature until nitrile band disappeared (monitored by IR 
analysis at 2200 cm-1). The corresponding imidate was filtered off, washed with dry diethyl 
ether and dried under reduced pressure. 
Amidines. The corresponding imidate was suspended in absolute ethanol and dry NH3 was 
bubbled into the suspension. The mixture was stirred at room temperature for 2 days. The crude 
product was then filtered off and washed with diethyl ether. 
Imidazolynilamidines. Ethylenediamine (EDA) was added to a suspension of the 
corresponding imidate in absolute ethanol (5 mL) and the mixture was stirred at reflux for 24 
h. The crude product was then filtered off and washed with diethyl ether. 
N-(5(6)-Amidinobenzimidazol-2-yl)-2,4-dimethoxybenzamide hydrochloride (38): This 
compound was prepared using above described method. A solution of 21 (0.18 g, 0.54 mmol) 
in absolute ethanol (20 mL) was saturated with dry HCl gas and stirred for 10 days. The crude 
imidate was filtered off, suspended in absolute ethanol (20 mL) and dry NH3 was bubbled into 
the suspension. The mixture was worked up as it is described to give 0.05 g (25%) of light 
yelow powder; mp 259˗˗262 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 11.08 (s, 1H, 
NHamide), 9.33 (s, 2H, NHamidine), 9.17 (s, 2H, NHamidine), 8.01 (s, 1H, Harom), 7.92 (d, J = 8.55 
Hz, 1H, Harom), 7.64 (d, J = 2.55 Hz, 1H, Harom), 6.78˗˗6.73 (m, 2H, Harom), 4.03 (s, 3H, OCH3), 
3.87 (s, 3H, OCH3); 13C NMR (150 MHz, DMSO-d6) (δ/ppm): 166.3, 164.3, 163.8, 159.2, 
148.6, 132.6 (2C), 121.4, 120.6, 120.5, 113.0, 106.6, 98.7 (2C), 56.6, 55.8; Anal. Calcd. for 
C17H18ClN5O3: C, 54.61; H, 4.65; N, 18.78. Found: C, 54.33; H, 4.83; N, 18.64.
 
N-(5(6)-Amidinobenzimidazol-2-yl)-3,4,5-trimethoxybenzamide hydrochloride (39): This 
compound was prepared using above described method. A solution of 22 (0.20 g, 0.57 mmol) 
in absolute ethanol (15 mL) was saturated with dry HCl gas and stirred for 6 days. The crude 
imidate was filtered off, suspended in absolute ethanol (20 mL) and dry NH3 was bubbled into 
the suspension. The mixture was worked up as it is described to give 0.16 g (69%) of white 
powder; mp 224˗˗226 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 12.76 (s, 1H, 
NHbenzimidazole), 12.21 (s, 1H, NHamide), 9.28 (s, 2H, NHamidine), 9.02 (s, 2H, NHamidine), 8.02 (1H, 
S4
s, Harom), 7.68 (d, J = 8.34 Hz, 1H, Harom), 7.63 (d, J = 8.46 Hz, 1H, Harom), 7.53 (s, 2H, Harom), 
3.91 (s, 6H, OCH3), 3.77 (s, 3H, OCH3); 13C NMR (75 MHz, DMSO-d6) (δ/ppm): not enough 
soluble; Anal. Calcd. for C18H20ClN5O2: C, 53.48; H, 4.75; N, 17.44. Found: C, 53.27; H, 4.97; 
N, 17.26. 
N-[5(6)-2-(Imidazolinyl)benzimidazol-2-yl]-2,4-dimethoxybenzamide hydrochloride (43): This 
compound was prepared using above described method. A solution of 21 (0.18 g, 0.54 mmol) 
in absolute ethanol (20 mL) was saturated with dry HCl gas and stirred for 10 days. The crude 
imidate was filtered off, suspended in absolute ethanol (20 mL) and EDA (0.107 ml, 1.61 mmol) 
was added into the suspension. The mixture was worked up as it is described to give 0.09 g 
(41%) of light yelow powder; mp 273˗˗275 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 11.41 
(s, 1H, NHamide), 10.79 (s, 2H, NHamidine), 8.29 (s, 1H, Harom), 7.97 (d, J = 8.49 Hz, 1H, Harom), 
7.95 (dd, J1 = 8.46 Hz, J2 =1.50 Hz, 1H, Harom), 7.78 (d, J = 8.49 Hz, 1H, Harom), 6.82 – 6.76 
(m, 2H, Harom), 4.02 (s, 3H, OCH3), 4.01 (s, 4H, CH2), 3.90 (s, 3H, OCH3); 13C NMR (75 MHz, 
DMSO-d6) (δ/ppm): 164.9, 163.3, 159.6, 147.3, 133.1, 123.4, 116.3, 115.0, 114.1, 111.8, 107.0, 
98.7, 56.8, 55.6, 44.2 (2C); Anal. Calcd. for C19H20ClN5O3: C, 56.95; H, 5.21; N, 17.24. Found: 
C, 56.79; H, 5.02; N, 17.43.  
N-[5(6)-2-(Imidazolinyl)benzimidazol-2-yl]-3,4,5-trimethoxybenzamide hydrochloride (44): 
This compound was prepared using above described method. A solution of 21 (0.20 g, 0.57 
mmol) in absolute ethanol (15 mL) was saturated with dry HCl gas and stirred for 6 days.  The 
crude imidate was filtered off, suspended in absolute ethanol (20 mL) and EDA (0.128 ml, 1.92 
mmol) was added into the suspension. The mixture was worked up as it is described to give 
0.15 g (61%) of white powder; mp 277˗˗279 °C; 1H NMR (300 MHz, DMSO-d6) (δ/ppm): 11.46 
(s, 1H, NHamide), 9.96 (s, 2H, NHamidine), 7.96 (d, J = 1.08 Hz, 1H, Harom), 7.65 (dd, J1 = 8.37 
Hz, J2 = 1.53 Hz, 1H,Harom), 7.51 (s, 2H, Harom), 7.48 (d, J = 8.43 Hz, 1H, Harom), 3.89 (s, 6H, 
OCH3), 3.76 (s, 3H, OCH3), 3.66 (s, 4H, CH2); 13C NMR (75 MHz, DMSO-d6) (δ/ppm): 167.2, 
165.3, 153.2, 150.4, 141.9, 138.6, 136.4, 128.9, 121.7, 115.2, 114.3, 113.7, 111.1, 106.9 (2C), 
60.6, 56.7 (2C), 48.4 (2C); Anal. Calcd. for C20H22ClN5O4: C, 55.85; H, 5.30; N, 16.38. Found: 
C, 55.62; H, 5.13; N, 16.22. 
S5


















































































































































































































































































Figure S4. 13C NMR spectrum (DMSO-d6, 150 MHz) of 2-hydroxy-4-methoxy-N-(4-
cyanophenyl)benzamide 8.





































































































Figure S7. 1H NMR spectrum (DMSO-d6, 300 MHz) of 3,4,5-trihydroxy-N-(4-



















































































































































































































Figure S10. 13C NMR spectrum (DMSO-d6, 150 MHz) of 2-hydroxy-N-(4-
amidinophenyl)benzamide 11.
Figure S11. 1H NMR spectrum (DMSO-d6, 600 MHz) of 2-hydroxy-4-methoxy-N-(4-































































Figure S12. 13C NMR spectrum (DMSO-d6, 150 MHz) of 2-hydroxy-4-methoxy-N-(4-

















































Figure S13. 1H NMR spectrum (DMSO-d6, 300 MHz) of 2,4-dihydroxy-N-(4-



























































Figure S14. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2,4-dihydroxy-N-(4-
amidinophenyl)benzamide 13.
PPM   14.0     13.0     12.0     11.0     10.0     9.0     8.0     7.0   













































x    0.142
  4.0   





Figure S15. 1H NMR spectrum (DMSO-d6, 600 MHz) of 2-hydroxy-N-[4-(imidazolin-2-
yl)phenyl]benzamide 14.  
S13
Figure S16. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2-hydroxy-N-[4-(imidazolin-2-
yl)phenyl]benzamide 14.  
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Figure S17. 1H NMR spectrum (DMSO-d6, 600 MHz) of 2-hydroxy-4-methoxy-N-[4-(imidazolin-
2-yl)phenyl]benzamide 15.  
Figure S18. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2-hydroxy-4-methoxy-N-[4-(imidazolin-
































































Figure S19. 1H NMR spectrum (DMSO-d6, 300 MHz) of 2,4-dihydroxy-N-[4-(imidazolin-2-






























































Figure S20. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2,4-dihydroxy-N-[4-(imidazolin-2-































































Figure S21. 1H NMR spectrum (DMSO-d6, 300 MHz) of 3,4,5-trihydroxy-N-[4-(imidazolin-



































Figure S22. 13C NMR spectrum (DMSO-d6, 75 MHz) of 3,4,5-trihydroxy-N-[4-(imidazolin-2-
yl)phenyl]benzamide 17.
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Figure S29. 1H NMR spectrum (DMSO-d6, 600 MHz) of 3,4,5-trimethoxy-N-(6-















































Figure S30. 13C NMR spectrum (DMSO-d6, 75 MHz) of 3,4,5-trimethoxy-N-(6-
cyanobenzothiazol-2-yl)benzamide 25.   
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Figure S31. 1H NMR spectrum (DMSO-d6, 300 MHz) of 2-hydroxy-N-[5(6)-cyano-1H-

































Figure S32. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2-hydroxy-N-[5(6)-cyano-1H-



























































































Figure S34. 13C NMR spectrum (DMSO-d6, 150 MHz) of 2-hydroxy-4-methoxy-N-[5(6)-
cyano-1H-benzimidazol-2-yl]benzamide 27.
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Figure S35. 1H NMR spectrum (DMSO-d6, 300 MHz) of 2-hydroxy-N-(6-cyanobenzothiazol-
2-yl)benzamide 28.




















































































































Figure S38. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2-hydroxy-4-methoxy-N-(6-
cyanobenzothiazol-2-yl)benzamide 29.
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Figure S41. 1H NMR spectrum (DMSO-d6, 300 MHz) of 2-hydroxy-4-methoxy -N-[5(6)-
amidino-1H-benzimidazol-2-yl]benzamide 31.





































































Figure S43. 1H NMR spectrum (DMSO-d6, 300 MHz) of 2-hydroxy-N-(6-















































Figure S44. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2-hydroxy-N-(6-













































Figure S45. 1H NMR spectrum (DMSO-d6, 300 MHz) of 2-hydroxy-4-methoxy-N-(6-
amidinobenzothiazol-2-yl)benzamide 33.
Figure S46. 13C NMR spectrum (DMSO-d6, 150 MHz) of 2-hydroxy-4-methoxy-N-(6-
amidinobenzothiazol-2-yl)benzamide 33.
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Figure S48. 13C NMR spectrum (DMSO-d6, 75 MHz) of 2-hydroxy-N-[5(6)-(imidazolinil-2-
yl)-1H-benzimidazol-2-yl]benzamide 34.
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Figure S54. 1H NMR spectrum (DMSO-d6, 600 MHz) of 2,4-dimethoxy-N-(6-
amidinobenzothiazol-2-yl)benzamide 41.
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Figure S58. 13C NMR spectrum (DMSO-d6, 150 MHz) of 2-methoxy-N-[6-(imidazolinil-2-
yl)benzothiazol-2-yl]benzamide 45.
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Figure S60. 13C NMR spectrum (DMSO-d6, 150 MHz) of 2,4-dimethoxy-N-[6-(imidazolinil-
2-yl)benzothiazol-2-yl]benzamide 46.
S36
Figure S61. 1H NMR spectrum (DMSO-d6, 600 MHz) of 3,4,5-trimethoxy-N-[6-(imidazolin-
2-yl)benzothiazol-2-yl]benzamide 47.






Stock solutions of the compounds were prepared in dimethyl sulfoxide (DMSO) at a concentration of 
10 mM and afterwards diluted with a nutrient medijum (RPMI 1640), supplemented with L-glutamine 
(3 mM), streptomycin (100 mg/ml) and penicillin (100 IU/ml), 10% heat inactivated (56 °C) fetal bovine 
serum (FBS) and 25 mM Hepes, adjusted to pH 7.2 by bicarbonate solution and applied to target cells 
to various final concentration ranging from 0 to 100 mM. 
Cell growing
HeLa cells were grown in RPMI1640 medium supplemented with L-glutamine, streptomycin- penicillin 
and 10% fetal bovine serum (FBS). HeLa cells were seeded (2000 cells per well) into 96-well flat-
bottomed microtiter plates and 24 h later, after the cell adherence, five different concentrations of 
investigated compounds were added to the wells. Only nutrient medium was added to the cells in the 
control wells with corresponding concentrations of DMSO. The nutrient medium with corresponding 
concentrations of compounds, but void of cells, was used as the blank. After 72 h of cultures incubation, 
the effect of the prepared compounds on cancer cell survival was determined by the microculture 
tetrazolium test (MTT) according to Mosmann1,2.
Determination of cell survival
Briefly, 20 mL of MTT solution (5 mg/mL phosphate-buffered saline) was added to each well. Samples 
were incubated for a further 4 h at 37°C in a humidified atmosphere of 95% air/5% CO2 (v/v). Then, 
100 mL of 100 g/L sodium dodecyl sulfate were added to the extract, resulting in formation of insoluble 
formazan by conversion of the MTT dye by viable cells. The number of viable cells in each well was 
proportional to the intensity of the absorbance of light, which was read in an enzyme-linked 
immunosorbent assay (ELISA) plate reader at 570 nm. The absorbance (A) at 570 nm was measured 24 
h later. To determine cell survival (%), A of the sample with cells grown in the presence of various 
concentrations of the investigated compounds was divided by the control optical density (A of control 
cells grown only in nutrient medium) and multiplied by 100. It was implied that A of the blank was 
always subtracted from A of the corresponding sample with target cells. IC50 was defined as the 
concentration of an agent inhibiting cell survival by 50% compared with a vehicle-treated control. As 
positive controls, cis-diamminedichloroplatinum (cisplatin) was used.
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4. Determination of antimicrobial activity
The antimicrobial activity was determinated using four different strains of the Gram-positive 
bacteria: Staphylococcus aureus (ATCC 6538), Micrococcus luteus (ATCC 4698), Clostridium 
sporogenes (ATCC 19404), Bacillus subtilis (ATCC 6633), four different strains of the Gram-
negative bacteria: Escherichia coli (ATCC 25922), Klebsiella pneumoniae (ATCC 10031), 
Proteus hauseri (ATCC 13315), Pseudomonas aeruginosa (ATCC 9027) and three strains of 
the fungi: Candida albicans (ATCC 10231), Sacharomyces cerevisiae (ATCC 9763) and 
Aspergillus brasiliensis (ATCC 16404). Antimicrobial activity was determinated by broth 
microdulution method.3 100 µL of fresh Mueller-Hinton broth (for bacteria) and Sabouraund 
dextrose broth (for fungi) were poured into all wells. Stock solutions of the compounds were 
prepared in dimethyl sulfoxide (concentration 10 mg/mL) and 100 μL of the compound stock 
solution were added to each well of the first column. Amikacin served as positive controls for 
bacteria, while nystatin served as positive controls for fungi. After the double dilution of the 
compounds, in each well 10 µL of bacterial suspension (106 cells) and 10 µL of fungi (105 
spores) were added. The microtiter plates were incubated at 37 °C for 24 h for bacteria or at 28 
°C for 48 h for fungi. The lowest concentration of compound that inhibited visible growth of a 
microorganism (MIC) was determined under a binocular microscope. When there is no 
microbial growth, the solution in the well remains clear while turbidity indicates the growth of 
microorganism.
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5. 3D-QSAR dataset 


























































































































































































































































































































































































Figure S63. PCA loadings plot. Molecular descriptors with the highest contributions to the 




Figure S64. Predicted residuals of: A) model 1 and B) model 2. Name of the compounds are 
given in Table 1S. 
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6. Determination of antioxidative activity
Free-radical scavenging antioxidant assay (DPPH method)
Free-radical scavenging antioxidant activity was assayed using a protocol for the determination 
of radical scavenging activity.6 Compounds were dissolved in pure DMSO and were diluted 
into ten different concentrations. Commercially available free radical DPPH was dissolved in 
methanol at a concentration of 6.58 x 10-5 M. Into a 96-well microplate, 140 μL of DPPH 
solution was loaded and 10 μL DMSO solution of the tested compounds was added, or pure 
DMSO (10 μL) as the control. The microplate was incubated for 30 min at 298 K in the dark 
and the absorbance was measured at 517 nm. All the measurements were carried out in 
triplicate. The scavenging activity of the compounds was calculated using the eq. (1):
Scavenging activity (%) = (Acontrol – Asample)/Acontrol × 100
where Asample and Acontrol refer to the absorbances at 517 nm of DPPH in the sample and control 
solutions, respectively. IC50 values were calculated from the plotted graph of scavenging 
activity against the concentrations of the samples. IC50 is defined as the total antioxidant 
concentration necessary to decrease the amount of the initial DPPH radical by 50%. IC50 was 
calculated for all compounds based on the percentage of DPPH radicals scavenged. Ascorbic 
acid was used as the reference compound (positive control) with concentrations 50 to 500 mg 
mL-1.
Superoxide test
Superoxide radicals are generated in PMS-NADH systems by oxidation of NADH and assayed 
by the reduction of NBT.7 In these experiments in microplate, the superoxide radicals were 
generated in  234 μL phosphate buffer (100 mM, pH 7.4) containing 6 μL of NBT (3.18 mM) 
solution, 6 μL NADH (12.72 mM) solution and 2.5 μL sample solution of fraction (25 – 500 
mg/ml) in methanol. The reaction started by adding 1.5 μL of PMS solution (1.28 mM) to the 
mixture. The reaction mixture was incubated at 25 °C for 5 min, the color change was monitored 
at 560 nm by spectrophotometer (ThermoScientific Appliscan, SkanIt version 2.3) against 
blank samples using ascorbic acid as a control. Decreased absorbance of the reaction mixture 
indicated the increasing of superoxide anion scavenging activity. All the measurements were 
carried out in triplicate. The percentage inhibition of superoxide anion generation was 
calculated using the following formula:
S48
% inhibition = [(A0-A1)/A0] x 100
where A0 was the absorbance of the control , and A1 was the absorbance in the presence of 
fraction or standards.
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